Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months

Pérez Encinas, Manuel Mateo

Estatísticas

Estatísticas

Ver Estatísticas de uso

Identificadores

Identificadores

URI: http://hdl.handle.net/20.500.11940/2944

PMID: 25756742

DOI: 10.1002/cam4.440

ISSN: 2045-7634

Rexistro completo

Servizos

Servizos

RIS

Mendeley

Linksolver

Data de publicación

2015

Tipo de contido

Artigo